PT - JOURNAL ARTICLE AU - HIRONORI BETSUNOH AU - SETSU SAKAMOTO AU - YASUSHI KAJI AU - AKINORI NUKUI AU - MINORU KOBAYASHI AU - MASAHIRO YASHI AU - KEITARO HAYASHI AU - NAOHIKO ANZAI AU - TAKAO KAMAI TI - Clinical Significance of <sup>18</sup>F-fluorodeoxyglucose and Glucose Transporter 1 mRNA in Clear Cell Renal Cell Carcinoma AID - 10.21873/anticanres.15336 DP - 2021 Oct 01 TA - Anticancer Research PG - 5179--5188 VI - 41 IP - 10 4099 - http://ar.iiarjournals.org/content/41/10/5179.short 4100 - http://ar.iiarjournals.org/content/41/10/5179.full SO - Anticancer Res2021 Oct 01; 41 AB - Background/Aim: 18F-fluorodeoxyglucose (FDG) uptake measurement on positron emission tomography/computed tomography (PET/CT) is difficult in renal tumors because of the nearby renal parenchyma and urinary tract, which excrete FDG. We carefully examined the maximum standardized uptake value (SUVmax) on FDG-PET/CT and investigated the relationship between major glucose transporters in the kidney and clear cell renal cell carcinoma (ccRCC) progression. Patients and Methods: Forty-five patients with ccRCC underwent FDG-PET/CT for staging and nephrectomy. Glucose transporter mRNA expression was examined in the removed kidney. Results: SUVmax was increased in high-stage and high-grade tumors. Glucose transporter 1 (GLUT1) mRNA expression was higher in tumor tissues, in contrast to other glucose transporters. SUVmax was not correlated with GLUT1 mRNA expression. Kaplan-Meier analysis showed reduced overall and recurrence-free survival in the high SUVmax group. Conclusion: Primary ccRCC lesions show a high SUVmax and GLUT1 mRNA over-expression. SUVmax increases with tumor upstaging and upgrading.